French Retail REITs Stock News

ENXTPA:ABVX
ENXTPA:ABVXBiotechs

ABIVAX (ENXTPA:ABVX) Q1 Loss Of €48.5 Million Tests Bullish Growth Narratives

ABIVAX Société Anonyme (ENXTPA:ABVX) opened Q1 2026 with revenue of €1.3 million and a loss of €48.5 million, equivalent to EPS of €0.61. This sets a clear picture of a business still investing heavily for future potential rather than current profitability. Over recent quarters, the company has reported revenue between €0.6 million and €4.3 million, while quarterly EPS ranged from €0.61 to €2.10 and quarterly net losses moved between €39.4 million and €153.4 million. This gives investors a...
ENXTPA:OR
ENXTPA:ORPersonal Products

A Look At L'Oréal (ENXTPA:OR) Valuation As The 2026 Big Bang Beauty Tech Program Launches

L'Oréal (ENXTPA:OR) has opened the 2026 Big Bang Beauty Tech Innovation Program, focusing on AI powered commerce, creator ecosystems, and sustainability, which has prompted fresh investor attention on how this approach might relate to the stock. See our latest analysis for L'Oréal. Despite the renewed focus on beauty tech and AI, L'Oréal's share price return has been softer recently, with the 30 day share price return down 4.19% and the 90 day share price return down 8.93%. The 5 year total...
ENXTPA:AIR
ENXTPA:AIRAerospace & Defense

Airbus Manslaughter Verdict Poses Fresh Questions For Valuation And Risk

Airbus has been found guilty of corporate manslaughter by a Paris appeals court over the 2009 Air France Flight 447 crash that killed 228 people. The ruling overturns earlier acquittals and imposes maximum corporate fines on Airbus. Both Airbus and Air France intend to appeal the decision to France’s highest court. The verdict lands at a time when ENXTPA:AIR trades at €169.52, with the stock up 9.8% over the past year and 71.1% over five years, while down 16.8% year to date. For investors,...
ENXTPA:MEDCL
ENXTPA:MEDCLPharmaceuticals

How Investors May Respond To MedinCell (ENXTPA:MEDCL) After EMA Accepts TEV-749 Schizophrenia Filing

Teva Pharmaceuticals International GmbH and MedinCell have announced that the European Medicines Agency has accepted their Marketing Authorization Application for TEV-749, a once-every-four-weeks subcutaneous olanzapine long-acting injectable for adult schizophrenia, supported by Phase 3 SOLARIS efficacy and safety data. The filing showcases MedinCell’s SteadyTeq copolymer delivery technology in a major psychiatric indication, potentially broadening the clinical and commercial reach of its...
ENXTPA:CAP
ENXTPA:CAPIT

How Dividend Move and AI Data Centre Bet May Reframe Capgemini's (ENXTPA:CAP) Investment Profile

At its Shareholders’ Meeting held on May 20, 2026, Capgemini SE approved a dividend of €3.40 per share for the 2025 financial year, confirmed multiple board renewals and new independent director appointments, and formalized governance changes including new heads of key committees. On the same day, Capgemini’s role in the AION consortium seeking EU backing for a €10.00 billion AI-focused data centre in France underscored its involvement in large-scale digital infrastructure while board...
ENXTPA:RMS
ENXTPA:RMSLuxury

A Look At Hermès International (ENXTPA:RMS) Valuation After Recent Share Price Weakness

Hermès International stock performance snapshot Hermès International Société en commandite par actions (ENXTPA:RMS) has drawn investor attention after a period of mixed share performance, with the stock down about 2% over the past month and roughly 24% over the past 3 months. See our latest analysis for Hermès International Société en commandite par actions. At a share price of €1,605.0, Hermès International’s recent 1-day and 7-day share price returns sit in contrast to a much weaker 90-day...
ENXTPA:TKO
ENXTPA:TKOCapital Markets

A Look At Tikehau Capital’s Valuation As Mixed Returns Meet An 18.7% Estimated Discount

What recent returns say about Tikehau Capital (ENXTPA:TKO) Tikehau Capital (ENXTPA:TKO) has delivered mixed share price performance, with the stock up 2.5% in the past day, slightly down over the past week and month, but positive over the past 3 months and year to date. See our latest analysis for Tikehau Capital. Putting this in context, the share price has positive momentum year to date, with a 13.29% year to date share price return. However, the 1 year total shareholder return is down...
ENXTPA:AM
ENXTPA:AMAerospace & Defense

Does Dassault Aviation (ENXTPA:AM)’s VORTEX‑S Bid Reframe Its Long‑Term Defense‑to‑Space Investment Story?

In May 2026, OHB announced that it had teamed up with Dassault Aviation and other European partners to propose VORTEX‑S, a multipurpose spaceplane for the European Space Agency, with Dassault as prime architect and OHB leading the service module. This collaboration expands Dassault Aviation’s role in European space mobility, potentially deepening its involvement in reusable space transport and autonomous orbital missions. Next, we’ll explore how Dassault’s role as prime architect of VORTEX‑S...
ENXTPA:NEX
ENXTPA:NEXElectrical

Nexans AGM Resolutions Shape Dividend Policy And Board Oversight

Nexans (ENXTPA:NEX) held its Annual General Meeting, where shareholders approved all 22 proposed resolutions. The agenda included a dividend increase, the appointment of two new independent Directors, and the renewal of several existing board members. These decisions represent a significant update to the company’s governance framework. Nexans, listed as ENXTPA:NEX, operates in the cable and connectivity sector, supplying infrastructure for energy and data networks. The broad approval of AGM...
ENXTPA:RNO
ENXTPA:RNOAuto

A Look At Renault (ENXTPA:RNO) Valuation After Landmark Dual Tranche Samurai Bond Issue

Renault (ENXTPA:RNO) has just tapped Japan’s Samurai bond market with a ¥159 billion dual tranche issue, split between retail and institutional investors, offering 3.02% coupons on bonds maturing in 2030. See our latest analysis for Renault. The Samurai bond issuance comes at a time when the stock has seen the share price fall 10.96% over the past month and 23.38% year to date, with a 1 year total shareholder return decline of 36.97%. Investors appear to be weighing funding moves like this...
ENXTPA:AL2SI
ENXTPA:AL2SITech

A Look At 2CRSI (ENXTPA:AL2SI) Valuation After Sector-Driven AI Infrastructure Rally

Sector-driven rally puts 2CRSI in focus 2CRSI (ENXTPA:AL2SI) moved higher after a broad rally in French semiconductor stocks, as enthusiasm around AI infrastructure, datacenters, and high performance computing put extra attention on the company. See our latest analysis for 2CRSI. The recent 3.73% 1 day share price return at a €46.7 close caps a strong run, with a 20.8% 7 day share price return and a 310.37% year to date share price return contributing to a very large 1 year total shareholder...
ENXTPA:EXE
ENXTPA:EXEMachinery

EXEL Industries (ENXTPA:EXE) Trailing Loss Challenges Bullish Margin Recovery Narratives

EXEL Industries (ENXTPA:EXE) has opened H1 2026 with trailing 12 month revenue of €920.5 million and a net loss of €4.0 million, setting a cautious tone around profitability. The company has seen half year revenue move from €606.6 million in H2 2024 to €443.4 million in H1 2025 and then €539.6 million in H2 2025, while basic EPS shifted from €3.87 to €0.20 and then €2.39 over the same periods, giving investors a clear view of how earnings power has been fluctuating against a relatively stable...
ENXTPA:ERA
ENXTPA:ERAMetals and Mining

Assessing ERAMET (ENXTPA:ERA) Valuation After Recent Share Price Cooling

Recent performance snapshot ERAMET (ENXTPA:ERA) has drawn attention after recent share price moves, with the stock down about 1% on the day and roughly 4% over the past week, yet slightly positive over the past month. See our latest analysis for ERAMET. At a share price of €53.4, ERAMET’s recent pullback, with weaker 7 day and year to date share price returns but a stronger 90 day move, contrasts with a 12.05% 1 year total shareholder return. This suggests that momentum has cooled after a...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

A Look At Sanofi (ENXTPA:SAN) Valuation After Positive ElevAATe Phase 2 AATD Emphysema Data

Why the ElevAATe data matters for Sanofi stock Sanofi (ENXTPA:SAN) has just put fresh clinical trial data in front of investors, with its ElevAATe phase 2 study showing that investigational efdoralprin alfa achieved normalized alpha-1 antitrypsin levels in AATD-related emphysema. The recombinant protein outperformed standard plasma-derived therapy on key efficacy measures and was reported as well tolerated, while fast track and orphan designations, plus active regulatory discussions, point to...
ENXTPA:SAF
ENXTPA:SAFAerospace & Defense

Safran Rides Cabin Modernization Theme With Valuation And Momentum Support

Safran is helping drive a global shift in aircraft cabin interiors, focusing on modernization, premium features, and connected technologies. Airlines worldwide are investing in new cabin equipment and digital environments to improve passenger comfort and connectivity. This trend highlights growing demand for lightweight, connected cabin solutions where Safran is an active supplier. With a current share price of €285.0, ENXTPA:SAF sits at the center of a key theme for the aviation supply...
ENXTPA:EXA
ENXTPA:EXAAerospace & Defense

Assessing Exail Technologies (ENXTPA:EXA) Valuation After New Indian Navy Mine Counter-Measure Contract

Larsen & Toubro Limited and Exail Technologies (ENXTPA:EXA) have agreed to supply an Unmanned Mine Counter Measure Suite for the Indian Navy, positioning Exail as the technology partner on 12 planned Mine Counter Measure Vessels. See our latest analysis for Exail Technologies. After this announcement, Exail’s recent share price momentum has been firm, with a 7-day share price return of 7.96% and a year-to-date share price return of 45.01%, set against a very large 5-year total shareholder...
ENXTPA:TEP
ENXTPA:TEPProfessional Services

Assessing Teleperformance (ENXTPA:TEP) Valuation After A Recent Share Price Rebound

How Teleperformance Stock Has Been Moving Recently Teleperformance (ENXTPA:TEP) has drawn investor attention after a sharp shift in recent performance, with the stock up around 31% over the past month and about 41% over the past 3 months. See our latest analysis for Teleperformance. While the recent 31% 1 month share price return and 41% 3 month share price return at €73.26 suggest short term momentum is building, the 1 year total shareholder return is still down 17.7%, pointing to a more...